Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
Key facts
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 33 people enrolled
- Started
- 1 Jun 2021
- Ended
- 20 Dec 2023
- Type of study
- Observational
- Treatments tested
- Ceftazidime-avibactam
- Record updated
- 10 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Critically ill patients with severe sepsis(CRO infections) and treated with CAZ-AVI(culture-confirmed CRO susceptible to CAZ-AVI)
- Age ≥ 18 years
- Expected ICU stay ≥48 hours
- Hemoglobin >70 g/L during the pharmacokinetic blood-sampling period;
- The patient or authorized persons agree and sign the informed consent
Who cannot take part
- Expected ICU stay <48 hours
- Pregnant woman
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective observational study is conducted at the First Affiliated Hospital of Zhejiang University School of Medicine from June 1, 2021 to January 1, 2024. The study aims to characterize the population pharmacokinetics of ceftazidime (CAZ) and avibactam (AVI) in critically ill patients receiving ceftazidime-avibactam (CAZ-AVI), including patients with and without renal replacement therapy (RRT). Plasma concentrations of CAZ and AVI will be measured after the first-dose and steady-state administrations. Population pharmacokinetic and pharmacokinetic/pharmacodynamic target-attainment analyses will be performed to explore dosing strategies according to renal function and RRT status.
Treatments tested
- Ceftazidime-avibactam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 September 2026